Phaseline

Companies › Vir Biotechnology

Vir Biotechnology: clinical trials, targets and expected readouts

6 active drug programs in 11 registered trials: 5 Phase 2, 4 Phase 3, 2 Phase 1; Infectious disease, Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Elebsiran
Apolipoprotein B (APOB) antisense oligonucleotide inhibitor
APOBPhase 3Viral HepatitisNov 2026
Tobevibart
AAV receptor antagonist
AAVRPhase 3Viral HepatitisNov 2026
VIR-2218
HDV biosynthesis inhibitor; targets delta antigen
–Phase 2Hepatitis D, ChronicNov 2031
VIR-3434
Hepatitis B virus surface antigen (HBsAg) inhibitor
–Phase 2Hepatitis D, Chronic; Hepatitis B, ChronicNov 2031
VIR-5818
HER2-targeting immunotherapy (bispecific antibody engaging HER2 and immune effector cells)
–Phase 1Locally Advanced or Metastatic HER2-Expressing CancersApr 2028
VIR-5525
EGFR-targeting immunotherapy
EGFRPhase 1Solid Tumor MalignanciesAug 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07142811TobevibartPhase 2Viral HepatitisInfectious diseaseNov 2026
NCT07142811ElebsiranPhase 2Viral HepatitisInfectious diseaseNov 2026
NCT07128550TobevibartPhase 3Viral HepatitisInfectious diseaseDec 2026
NCT07128550ElebsiranPhase 3Viral HepatitisInfectious diseaseDec 2026
NCT05356741VIR-5818Phase 1Locally Advanced or Metastatic HER2-Expressing CancersOncologyApr 2028
NCT06960395VIR-5525Phase 1Solid Tumor MalignanciesOncologyAug 2029
NCT06216470VIR-3434Phase 2Hepatitis B, ChronicInfectious diseaseDec 2029
NCT06903338TobevibartPhase 3Viral HepatitisInfectious diseaseMay 2031
NCT06903338ElebsiranPhase 3Viral HepatitisInfectious diseaseMay 2031
NCT05461170VIR-2218Phase 2Hepatitis D, ChronicInfectious diseaseNov 2031
NCT05461170VIR-3434Phase 2Hepatitis D, ChronicInfectious diseaseNov 2031

From the company's SEC filings

Cash and short-term investments of $455m on 2026-09-30; operating cash outflow about $155m a year; runway about 35 months at that burn, to Sep 2029; 2 of 5 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

AAVR (1) APOB (1) EGFR (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group

Companies built like this

Serum Institute of India Suzhou Abogen Biosciences Sanaria Eveliqure Biotechnologies Brii Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.